Copeland Capital Management LLC Sells 2,635 Shares of Cencora, Inc. $COR

Copeland Capital Management LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 4.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,742 shares of the company’s stock after selling 2,635 shares during the period. Copeland Capital Management LLC’s holdings in Cencora were worth $16,484,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of COR. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC grew its stake in Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caldwell Trust Co bought a new position in Cencora in the second quarter worth $46,000. Capital A Wealth Management LLC raised its holdings in Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after purchasing an additional 159 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in Cencora during the second quarter valued at $52,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Robert W. Baird set a $392.00 target price on shares of Cencora in a research report on Tuesday, December 16th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 22nd. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $373.25.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the sale, the chief executive officer owned 68,059 shares in the company, valued at $23,374,863.55. This represents a 6.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock valued at $7,009,260 in the last 90 days. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

Shares of NYSE COR opened at $340.08 on Tuesday. The firm has a market cap of $65.97 billion, a P/E ratio of 42.78, a PEG ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The company has a 50 day moving average of $348.91 and a 200 day moving average of $315.59.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the company earned $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.